APA (7th ed.) Citation

Braulke, F., Nolte, F., Hofmann, W., & Schlenk, R. F. (2017). Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: Results of the LE-MON-5 trial. Annals of hematology, 96(6), . https://doi.org/10.1007/s00277-017-2983-0

Chicago Style (17th ed.) Citation

Braulke, Friederike, Florian Nolte, Wolf-Karsten Hofmann, and Richard Friedrich Schlenk. "Peripheral Blood Cytogenetics Allows Treatment Monitoring and Early Identification of Treatment Failure to Lenalidomide in MDS Patients: Results of the LE-MON-5 Trial." Annals of Hematology 96, no. 6 (2017). https://doi.org/10.1007/s00277-017-2983-0.

MLA (9th ed.) Citation

Braulke, Friederike, et al. "Peripheral Blood Cytogenetics Allows Treatment Monitoring and Early Identification of Treatment Failure to Lenalidomide in MDS Patients: Results of the LE-MON-5 Trial." Annals of Hematology, vol. 96, no. 6, 2017, https://doi.org/10.1007/s00277-017-2983-0.